Navigation Links
Phase 3 Topical Drug for Raynaud's Disease Available for Licensing/Acquisition at the J.P. Morgan Conference
Date:12/13/2012

BOTHELL, Wash., Dec. 13, 2012 /PRNewswire-iReach/ -- MediQuest Therapeutics Inc., a specialty pharmaceutical company focused on inflammatory skin diseases and conditions, today announced that they will be conducting partnering/M&A meetings at the J.P. Morgan 31st Annual Healthcare Conference between January 7th and 10th in San Francisco, regarding its Phase 3 topical formulation, VASCANA, designed to treat Raynaud's Disease, an unmet medical need. MediQuest is also selling/licensing the remainder of its topical assets including a skin lightener, ready for commercialization.  Its topical/non-systemic Onychomycosis drug was out-licensed in August 2012.

(Photo: http://photos.prnewswire.com/prnh/20121213/CG29278)

MediQuest's VASCANA has a Special Protocol Assessment granted by the Federal Food & Drug Administration for a single Phase 3 study involving approximately 150 patients that suffer from moderate to severe symptoms of Raynaud's Syndrome.  VASCANA has a strong safety profile and an extensive intellectual property portfolio with issued patents that run to 2026.   The peak sales in the United States is estimated at about $250 million, as well as similar markets in EU and Asia, with low cost of goods, supported by 2-years of stability data.

Any company interested in learning more about VASCANA can arrange to meet with MediQuest at the J.P. Morgan conference through the below contact information.  

About Raynaud's Disease
An estimated 9-11 million people in the United States suffer from Raynaud's Disease, 2.1 million of which have been diagnosed and are seeking medical treatment. Raynaud's patients can experience severe pain associated with chronic vasospasm episodes in their hands, feet and other extremities.

About MediQuest Therapeutics, Inc.
MediQuest Therapeutics is a specialty pharmaceutical company using its proprie
'/>"/>

SOURCE MediQuest Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lilly Discontinues One of Three Phase 3 Rheumatoid Arthritis Registration Studies for Tabalumab
2. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
3. Insero Health Completes Phase I Trial of Novel Therapy in Patients With Drug Resistant Epilepsy
4. Unigenes Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
5. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
6. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
7. uniQure Initiates Phase I in Acute Intermittent Porphyria
8. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
9. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
10. Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
11. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)...   , July 2, 2015 BGI ... Hong Kong has been accredited ... Kong facility is the first clinical next-generation-sequencing laboratory to ... , meeting the highest standard in clinical laboratory practices. Complementary ... 11 compliant laboratory process, and multiple ISO certifications, the ...
(Date:7/1/2015)... The Coalition of State Rheumatology Organizations ... professional rheumatology societies, today released the findings of ... of biosimilars and the potential impact of these ... are medicines that are highly similar, but not ... from generic medications in that it is impossible ...
(Date:7/1/2015)... -- Eli Lilly and Company (NYSE: LLY ) will ... on Thursday, July 23, 2015. Lilly will also conduct a ... media to further detail the company,s financial performance. ... media and the general public can access a live webcast ... posted on Lilly,s website at www.lilly.com . A replay ...
Breaking Medicine Technology:BGI Receives Accreditation from the College of American Pathologists (CAP) 2Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2Lilly Confirms Date and Conference Call for Second-Quarter 2015 Financial Results Announcement 2
... Mylan Inc. (Nasdaq: MYL ) today ... entered into a settlement agreement with Warner Chilcott resolving ... as Norethindrone and Ethinyl Estradiol Tablets USP (Chewable), 0.4 ... mg (28-Day Regimen). This medication is an oral contraceptive. ...
... NEW YORK, Oct. 19, 2011 Reportlinker.com announces ... in its catalogue: Syncria ... 2020 http://www.reportlinker.com/p0657174/Syncria-Type-2-Diabetes-–-Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... and Forecasts to 2020 Summary ...
Cached Medicine Technology:Mylan Announces Femcon® Fe Settlement Agreement 2Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 2Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 3Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 4Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 5
(Date:7/2/2015)... , ... July 02, 2015 , ... After conducting a ... Yuma Regional Medical Center in Yuma, Ariz., has hired Robert Trenschel, DO, ... healthcare and medical management, Dr. Trenschel will assume his new duties at Yuma Regional ...
(Date:7/2/2015)... ... July 02, 2015 , ... The report ... Capsule manufacturers. The report is a valuable source of guidance and direction for ... and Chinese market for the Gelatin Capsule industry including capacity, production, production value, ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... is announcing with their launch an intention to partner with companies that share ... on the planet. Their innovative water soluble, Cannabidiol (CBD) formulations, combined with Ayurvedic ...
(Date:7/2/2015)... AL (PRWEB) , ... July 02, 2015 , ... Every year, DUI arrests and fatalities ... July may be the deadliest day of the year when it comes to being on ... “The National Highway Traffic Safety Association reports that 40% of all highway deaths between 2007 ...
(Date:7/2/2015)... ... 2015 , ... Today, East Liverpool City Hospital announced Pam Akin, RN, MSN, ... Hospital (ELCH). Pam is currently the Chief Nursing Officer at ELCH and will remain ... a master’s degree in health care administration as well as nursing. She has a ...
Breaking Medicine News(10 mins):Health News:Yuma Regional Medical Center Hires New Chief Executive Officer 2Health News:Yuma Regional Medical Center Hires New Chief Executive Officer 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 2Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 4Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 2Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 3Health News:Attorney David Maloney Stresses Safety through Sobriety 2Health News:East Liverpool City Hospital Announces New Surgical Center Leadership 2Health News:East Liverpool City Hospital Announces New Surgical Center Leadership 3
... Francisco Bay Area Affiliate of Susan G. Komen for the ... to applaud the introduction of the 21st Century Cancer ALERT ... Detection, R esearch and T reatment) Act, bipartisan ... and Kay Bailey Hutchison (R-TX). "It,s been more than ...
... from fertility clinic embryos that otherwise would be discarded ... to use U.S. funding for embryonic stem cell research ... would be discarded, the National Institutes of Health announced ... research -- such as using stem cells taken from ...
... April 17 Even though suicide outranks homicide as ... death certificates thwart healthcare policymakers who want to create ... a WVU study shows."The Institute of Medicine ... have been diagnosed with a mental disorder, but death ...
... United States Great Depression of 1929 has the American ... well-being across the parameters of occupational, spiritual, emotional, and ... people are at risk for suffering lowered self esteem, ... St. Thomas University Counseling Programs - initiated ...
... Penny Imaging Exchange has acquired new German technology to process the ... ... Bohemia, NY (Vocus) April 17, 2009 -- Penny Imaging ... the conversion of microfiche records to digital form - the ...
... (Nasdaq: SUAI ) ("SUA" or the ... leading independent proxy advisory firm, has recommended that stockholders vote ... nominees recommended by dissident stockholder Hallmark Financial Services, Inc. ("Hallmark"). ... 9:00 a.m. local time on May 5, 2009 at 222 ...
Cached Medicine News:Health News:San Francisco Bay Area Affiliate of Susan G. Komen for the Cure(R) Applauds Introduction of Bipartisan Cancer Alert Act 2Health News:San Francisco Bay Area Affiliate of Susan G. Komen for the Cure(R) Applauds Introduction of Bipartisan Cancer Alert Act 3Health News:NIH May Ease Some, But Not All, Stem Cell Restrictions 2Health News:NIH May Ease Some, But Not All, Stem Cell Restrictions 3Health News:NIH May Ease Some, But Not All, Stem Cell Restrictions 4Health News:Team Uncovers Discrepancy in Death Certificates Listing Suicide 2Health News:Good News for Tough Times: Small, Private University Responds to Today's Economic Challenges 2Health News:Penny Imaging Exchange, Inc. Acquires New Technology to Capture Medical Records from Microfiche 2Health News:Penny Imaging Exchange, Inc. Acquires New Technology to Capture Medical Records from Microfiche 3Health News:Leading Independent Proxy Advisory Firm Supports Specialty Underwriters' Alliance, Inc. in Its Proxy Contest Against Hallmark Financial Services, Inc. 2Health News:Leading Independent Proxy Advisory Firm Supports Specialty Underwriters' Alliance, Inc. in Its Proxy Contest Against Hallmark Financial Services, Inc. 3
... Digital Flexible Ureteroscope (DUR-D) incorporates many ... proven durable, market leading DUR® series ... first device utilizing Gyrus ACMIs proprietary, ... Metal Oxide Semi-Conductor (CMOS) distal sensor ...
... is the first one-step 20 minutes rapid test ... 2 produced by Enterohemorrhagic Escherichia coli in human ... enrichment of fecal specimens and detects all Toxigenic ... separate result for Toxin 1 and 2 is ...
Inquire...
... elegant and sophisticated woman, the ... ophthalmic and sunwear styles. Frames ... of shapes and colors, designed ... and complexions. Many styles feature ...
Medicine Products: